COMPANY

Paragonix Technologies

Profile checked Oct 10, 2026

Keywords: Pancreas (Including SPK) Transplantation Pancreas Diseases Pancreas Transplant Rejection Interstitial Lung Disease COPD Cystic Fibrosis Pulmonary Fibrosis Pulmonary Arterial Hypertension Emphysema Liver Diseases Liver Dysfunction Liver Transplant Disorder Liver Transplant Rejection Lung Transplant Rejection Heart Diseases Heart Failure Congenital Heart Defects PancreasPak LIVERguard SherpaPak Cardiac Transport System

5Trials (company is sponsor)2FDA records (2 yrs)

Timeline

2027-01 Trial start —: Global Utilization And Registry Database for Improved preservAtion of doNor Pancreata (GUARDIAN-PANCREAS) source ↗
Jan 30, 2026 FDA FDA 510(k) clearance: BAROguard Donor Lung Preservation System — K254305, Jan 30, 2026. Applicant at approval: Paragonix Technologies, Inc. source ↗
Oct 23, 2024 FDA FDA 510(k) clearance: KIDNEYvault Portable Renal Perfusion System — K234060, Oct 23, 2024. Applicant at approval: Paragonix Technologies. source ↗
Sep 21, 2023 Trial start —: Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy source ↗
Mar 15, 2022 Trial start —: Global Utilization And Registry Database for Improved preservAtion of doNor Livers source ↗
Oct 15, 2021 Trial start —: Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs source ↗
Feb 14, 2020 Trial start —: Global Utilization And Registry Database for Improved heArt preservatioN source ↗

Upcoming milestones

2027-08 (ESTIMATED) · · Global Utilization And Registry Database for Improved preservAtion of doNor Livers · NCT05082077
Dec 31, 2027 (ESTIMATED) · · Global Utilization And Registry Database for Improved heArt preservatioN · NCT04141605
Jun 15, 2028 (ESTIMATED) · · Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs · NCT04930289
2031-06 (ESTIMATED) · · Global Utilization And Registry Database for Improved preservAtion of doNor Pancreata (GUARDIAN-PANCREAS) · NCT07487194

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07487194	Global Utilization And Registry Database for Improved preservAtion of doNor Pancreata (GUARDIAN-PANCREAS)	Not listed	Not yet recruiting	2027-01	2031-06 (estimated)
NCT04930289	Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs	Not listed	Enrolling by invitation	Oct 15, 2021	Jun 15, 2028 (estimated)
NCT05082077	Global Utilization And Registry Database for Improved preservAtion of doNor Livers	Not listed	Enrolling by invitation	Mar 15, 2022	2027-08 (estimated)
NCT06309628	Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy	Not listed	Terminated	Sep 21, 2023	May 9, 2025 (actual)
NCT04141605	Global Utilization And Registry Database for Improved heArt preservatioN	Not listed	Enrolling by invitation	Feb 14, 2020	Dec 31, 2027 (estimated)

FDA records (last 2 years)

Jan 30, 2026 FDA 510(k) clearance: BAROguard Donor Lung Preservation System — K254305, Jan 30, 2026. Applicant at approval: Paragonix Technologies, Inc. source ↗
Oct 23, 2024 FDA 510(k) clearance: KIDNEYvault Portable Renal Perfusion System — K234060, Oct 23, 2024. Applicant at approval: Paragonix Technologies. source ↗

Connect

See your connections at Paragonix Technologies on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12